A Non-interventional, Observational Study for Targinact® Treatment in Patients With Severe Pain.
CompletedNCT01983137
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This non-interventional, observational study evaluates the efficacy of Targinact with regard to pain relief in daily clinical practice in Belgium compared to the previous analgesic treatment.
Study details
- Official title
- The Efficacy, With Regard to Pain Relief, of Targinact® Treatment for Patients With Severe Pain Compared to Previous Analgesic Treatment; a Non-interventional Study.
- Conditions
- Severe Pain
- Interventions
- Drug: Targinact® (oxycodone/naloxone)
- Sponsor
- Mundipharma CVA
- Start date
- 2011-04
- Primary completion
- 2012-12
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Belgium
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion criteria: Patients who are to be included in the study, are those who meet all of the following criteria based on the SPC. 1. Male or female patients at least 18 years, or older, with severe pain. 2. Patients with documented history of severe pain treated with WHO step 1, step 2 and/or 3 analgesics with insufficient pain relief and/or unacceptable side effects that require around-the-clock opioid therapy and are likely to benefit from WHO step 3 opioid therapy for the duration of the study. Exclusion criteria are based on the SPC of Targinact®.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01983137